The U.S. Patent and Trademark Office (USPTO) has granted PharmAla Biotech Holdings (OTC:MDXXF) a national patent covering the composition of matter of its lead novel compound, ALA-002. The Novel Chemical Entity (NCE) is among the group of MDXX-class molecules under development by the biotech. Specifically, ALA-002 is a novel mixture of MDMA enantiomers: 70-80% R-MDMA, and 20-30% S-MDMA. “MDMA is relatively unique in that it has two enantiomers that are active, but are active in dramatically different ways,” explained the company’s Research VP Dr. Harpreet Kaur. “In the brain, these two variant…